“This guideline provides recommendations for designing, conducting, and interpreting enzyme- or transporter-mediated Drug-drug Interaction (DDI) studies during the development of therapeutic products. Key points include:

  1. Guideline Overview:
  • Published by ICH on 21-May-2024.
  • Adopted by the European Union on 30-May-2024 (effective 30-Nov-2024) and by the US FDA on 02-Aug-2024
  1. Evaluating DDI Potential:
  • Investigational drugs should be evaluated both as an object (affected by other drugs) and as a precipitant (affecting other drugs).
  • The primary elimination routes of the investigational drug must be identified.
  1. In Vitro Studies:
  • Before clinical phases, in vitro data on the drug as a substrate of metabolic enzymes should be obtained to assess metabolic stability.
  • Data on the investigational drug’s effect as a precipitant on major cytochrome P450 (CYP) enzymes and transporters should also be gathered.
  1. Clinical DDI Studies:
  • Clinical studies should follow mechanistic knowledge and provide recommendations for managing DDIs.
  • Study design and data analysis must be justified based on DDI mechanisms and pharmacokinetic properties.
  1. DDI Management:
  • Risk assessment should guide DDI prevention and risk minimization strategies.
  • Management should ensure substrate drug concentrations stay within the no-effect boundaries.

Source:https://www.ich.org/news/ich-m12-guideline-reaches-step-4-ich-process##~https://database.ich.org/sites/default/files/ICH_M12_Step4_Guideline_2024_0521_0.pdf##~https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m12-guideline-drug-interaction-studies-step-5_en.pdf##~https://www.ema.europa.eu/en/ich-m12-drug-interaction-studies-scientific-guideline##~https://www.fda.gov/media/161199/download##~https://www.regulations.gov/docket/FDA-2022-D-1527/document##~https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies

Region: All Markets, EU Harmonized (27 Markets), United States of America

pattern
pattern
Got questions? We’ve got answers!

Let's talk Regulatory!

Reach out to us and let’s unravel your Regulatory puzzle together. Unlock regulatory solutions with our global subject matter experts and tap into a wealth of regulatory intelligence.

Speak to an Expert